Maxim Group initiated coverage of Oncternal Therapeutics (NASDAQ:ONCT) with a “buy” rating and price target of $3.50. The stock closed at 99 cents on May 9. Oncternal is a clinical-stage company focused on novel targets...
BTIG launched coverage of Oncternal Therapeutics (NASDAQ:ONCT) with a “buy” rating and $5 price target. The stock closed at $1.73 on Feb. 23. Oncternal is a clinical-stage biotechnology company focused on a diverse...
The FDA granted Oncternal Therapeutics’ (NASDAQ:ONCT) TK216 rare pediatric disease designation for the treatment of Ewing sarcoma. Ewing sarcoma is the second most common bone tumor among children and adolescents, with...